Kumpulan Info tentang,
UNIVERSITAS SURABAYA
| No | Source Title | CiteScore | Quartile | Publisher | Highest percentile | Citations 2021-24 | Documents 2021-24 |
|---|---|---|---|---|---|---|---|
| 12511 | Molecular Therapy Methods and Clinical Development | 8.7 | Q1 | Elsevier | 84.0% 56/348 Genetics | 6032 | 696 |
| 12512 | Cell Stress | 6.7 | Q1 | Shared Science Publishers OG | 84.0% 20/125 Biochemistry, Genetics and Molecular Biology (miscellaneous) | 373 | 56 |
| 12513 | Cellular Oncology | 8.3 | Q1 | Springer Nature | 82.0% 74/415 Oncology | 3496 | 422 |
| 12514 | Molecular Biomedicine | 9.1 | Q1 | Springer Nature | 81.0% 34/177 Molecular Medicine | 1793 | 196 |
| 12515 | Expert Reviews in Molecular Medicine | 8.7 | Q1 | Cambridge University Press | 80.0% 35/177 Molecular Medicine | 1170 | 134 |
| 12516 | Analytical Cellular Pathology | 5.6 | Q1 | John Wiley & Sons | 79.0% 42/204 Pathology and Forensic Medicine | 1156 | 207 |
| 12517 | Vaccine: X | 3.5 | Q1 | Elsevier | 79.0% 41/200 General Veterinary | 1630 | 462 |
| 12518 | Pharmaceuticals | 7.7 | Q1 | Multidisciplinary Digital Publishing Institute (MDPI) | 79.0% 39/185 Pharmaceutical Science | 48523 | 6311 |
| 12519 | Journal of Cellular and Molecular Medicine | 8.7 | Q1 | John Wiley & Sons | 79.0% 36/177 Molecular Medicine | 22044 | 2535 |
| 12520 | FASEB BioAdvances | 5.6 | Q1 | John Wiley & Sons | 78.0% 28/125 Biochemistry, Genetics and Molecular Biology (miscellaneous) | 1292 | 229 |
| 12521 | Molecular Pain | 4.7 | Q1 | SAGE | 75.0% 35/139 Anesthesiology and Pain Medicine | 1125 | 237 |
| 12522 | Cancer Biology and Therapy | 6.2 | Q2 | Taylor & Francis | 74.0% 107/415 Oncology | 1937 | 313 |
| 12523 | SLAS Discovery | 6.7 | Q2 | Society for Laboratory Automation and Screening (SLAS) | 70.0% 47/160 Analytical Chemistry | 1897 | 285 |
| 12524 | Frontiers in Genetics | 6.2 | Q2 | Frontiers Media S.A. | 69.0% 31/100 Genetics (clinical) | 55811 | 8931 |
| 12525 | Journal of Pharmacological Sciences | 6.2 | Q2 | Japanese Pharmacological Society | 67.0% 104/321 Pharmacology | 2381 | 385 |
| 12526 | Function | 5.8 | Q2 | Oxford University Press | 64.0% 68/190 Physiology | 1239 | 213 |
| 12527 | Human Genetics and Genomics Advances | 5.8 | Q2 | Elsevier | 63.0% 37/100 Genetics (clinical) | 1445 | 250 |
| 12528 | Biomarker Insights | 5.3 | Q2 | SAGE | 63.0% 28/76 Biochemistry (medical) | 417 | 78 |
| 12529 | Molecular Imaging | 3.9 | Q2 | SAGE | 62.0% 129/346 Radiology, Nuclear Medicine and Imaging | 223 | 57 |
| 12530 | Exploration of Medicine | 1.8 | Q2 | Open Exploration Publishing Inc | 60.0% 267/668 General Medicine | 419 | 231 |
| 12531 | Clinical and Translational Discovery | 1.9 | Q2 | John Wiley & Sons | 60.0% 266/668 General Medicine | 264 | 141 |
| 12532 | Human Genomics | 5.4 | Q2 | Springer Nature | 59.0% 143/348 Genetics | 2027 | 378 |
| 12533 | GigaByte | 3.2 | Q2 | GigaScience Press | 58.0% 53/125 Biochemistry, Genetics and Molecular Biology (miscellaneous) | 436 | 136 |
| 12534 | European Journal of Medicinal Chemistry Reports | 5 | Q2 | Elsevier | 57.0% 53/124 Chemistry (miscellaneous) | 1132 | 228 |
| 12535 | AIDS Research and Therapy | 4 | Q2 | Springer Nature | 53.0% 128/275 Pharmacology (medical) | 1429 | 353 |
| 12536 | Biomimetics | 4.2 | Q3 | Multidisciplinary Digital Publishing Institute (MDPI) | 48.0% 161/314 Biotechnology | 7237 | 1706 |
| 12537 | Clinical Proteomics | 4.3 | Q3 | Springer Nature | 47.0% 64/121 Clinical Biochemistry | 834 | 193 |
| 12538 | Pharmacogenomics and Personalized Medicine | 4.2 | Q3 | Dove Medical Press | 46.0% 171/321 Pharmacology | 1523 | 366 |
| 12539 | Molecular Cytogenetics | 2.8 | Q3 | Springer Nature | 45.0% 42/76 Biochemistry (medical) | 495 | 175 |
| 12540 | EJNMMI Reports | 2.5 | Q3 | Springer Nature | 45.0% 189/346 Radiology, Nuclear Medicine and Imaging | 336 | 132 |